Research programme: drug abuse therapeutics - Synosia/RocheAlternative Names: SYN-119
Latest Information Update: 29 Mar 2011
At a glance
- Originator Roche
- Developer Synosia Therapeutics
- Mechanism of Action Metabotropic glutamate receptor type 1 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Drug abuse